Acquired multidrug antifungal resistance in Candida lusitaniae during therapy

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7715-7722

  Asner, Sandra A ^a   Giulieri, Stefano ^a   Diezi, Manuel ^a   Marchetti, Oscar ^a   Sanglard, Dominique ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BUSULFAN; CASPOFUNGIN; CIDOFOVIR; CLOFARABINE; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUDARABINE; GALACTOMANNAN; MICAFUNGIN; PYRROLE DERIVATIVE; THYMOCYTE ANTIBODY; VORICONAZOLE; ANTIFUNGAL AGENT; BETA GLUCAN; FUNGAL DNA; MANNAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADD ON THERAPY; ADENOVIRUS INFECTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BLOOD CULTURE; CANDIDEMIA; CASE REPORT; CHILD; CLAVISPORA LUSITANIAE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROCOLITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IMMUNOCOMPROMIZED PATIENT; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LUNG ASPERGILLOSIS; LUNG INFILTRATE; MACULOPAPULAR RASH; MONOTHERAPY; MULTIDRUG RESISTANCE; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PERSISTENT INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; RANDOM AMPLIFIED POLYMORPHIC DNA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION; VIRUS LOAD; AMINO ACID SEQUENCE; CANDIDA; CANDIDIASIS; COMPLICATION; DRUG EFFECTS; DRUG MONITORING; GENETICS; IMMUNOCOMPROMISED PATIENT; INFANT; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MUTATION;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA; CANDIDIASIS; DNA, FUNGAL; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, FUNGAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; LEUKEMIA, MYELOID, ACUTE; MANNANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84954491041     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02204-15     Document Type: Article

References (48)

1. Favel A, Michel-Nguyen A, Peyron F, Martin C, Thomachot L, Datry A, Bouchara JP, Challier S, Noel T, Chastin C, Regli P. 2003. Colony morphology switching of Candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. Diagn Microbiol Infect Dis 47:331-339. http: //dx.doi.org/10.1016/S0732-8893(03)00094-4.
2. Atkinson BJ, Lewis RE, Kontoyiannis DP. 2008. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 46:541-546. http://dx.doi.org/10.1080/1369378080 1968571.
3. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50:3435-3442. http://dx.doi.org /10.1128/JCM.01283-12.
4. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41:2333-2338.
5. Perlin DS. 2011. Echinocandin-resistant Candida: molecular methods and phenotypes. Curr Fungal Infect Rep 5:113-119. http://dx.doi.org/10.1007/s12281-011-0054-x.
6. Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59:1076-1083. http://dx.doi.org/10.1093/jac/dkm095.
7. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50:2058-2063. http: //dx.doi.org/10.1128/AAC.01653-05.
8. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E; European Committee on Antibiotic Susceptibility Testing. 2008. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother 52:3092-3098. http: //dx.doi.org/10.1128/AAC.00088-08.
9. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M, Bonilla H. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 54: 2225-2227. http://dx.doi.org/10.1128/AAC.00998-09.
10. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 51:1876-1878. http://dx.doi.org/10.1128/AAC.00067-07.
11. Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G, Flattery A, Gill C, Chrebet G, Parent SA, Kurtz M, Teppler H, Douglas CM, Perlin DS. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49:3264-3273. http://dx.doi.org/10.1128/AAC.49.8.3264-3273.2005.
12. Arendrup MC, Garcia-Effron G, Lass-Florl C, Lopez AG, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother 54:426-439. http://dx.doi.org/10.1128/AAC.01256-09.
13. Arendrup MC, Perlin DS. 2014. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 27:484-492. http://dx.doi.org/10.1097/QCO.0000000000000111.
14. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 55:561-566. http://dx.doi.org/10.1128 /AAC.01079-10.
15. Eddouzi J, Hofstetter V, Groenewald M, Manai M, Sanglard D. 2013. Characterization of a new clinical yeast species, Candida tunisiensis sp. nov., isolated from a strain collection from Tunisian hospitals. J Clin Microbiol 51:31-39. http://dx.doi.org/10.1128/JCM.01627-12.
16. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. 1992. Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol 30:3005-3008.
17. Sanglard D, Ischer F, Monod M, Bille J. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40:2300-2305.
18. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
19. Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F. 2011. Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J Clin Microbiol 49:2304-2306. http://dx.doi.org/10.1128/JCM.00325-11.
20. Eddouzi J, Parker JE, Vale-Silva LA, Coste A, Ischer F, Kelly S, Manai M, Sanglard D. 2013. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother 57:3182-3193. http://dx.doi.org/10.1128/AAC.00555-13.
21. Ferrari S, Sanguinetti M, Torelli R, Posteraro B, Sanglard D. 2011. Contribution of CgPDR1-regulated genes in enhanced virulence of azoleresistant Candida glabrata. PLoS One 6:e17589. http://dx.doi.org/10.1371 /journal.pone.0017589.
22. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49:668-679. http://dx.doi.org/10.1128/AAC.49.2.668-679.2005.
23. Reboutier D, Piednoel M, Boisnard S, Conti A, Chevalier V, Florent M, Gibot-Leclerc S, Da Silva B, Chastin C, Fallague K, Favel A, Noel T, Ruprich-Robert G, Chapeland-Leclerc F, Papon N. 2009. Combination of different molecular mechanisms leading to fluconazole resistance in a Candida lusitaniae clinical isolate. Diagn Microbiol Infect Dis 63:188-193. http://dx.doi.org/10.1016/j.diagmicrobio.2008.10.019.
24. Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E. 2014. CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res 42:W401-W407. http://dx.doi.org/10.1093/nar /gku410.
25. Mans R, van Rossum HM, Wijsman M, Backx A, Kuijpers NG, van den Broek M, Daran-Lapujade P, Pronk JT, van Maris AJ, Daran JM. 2015. CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. FEMS Yeast Res 15:fov004. http://dx.doi.org/10.1093/femsyr/fov004.
26. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O. 2010. Multiplex ultraperformance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother 54:5303-5315. http://dx.doi.org/10.1128/AAC.00404-10.
27. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S; European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. 2012. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 47:846-854. http://dx.doi.org/10.1038/bmt.2011.178.
28. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C; Third European Conference on Infections in Leukemia Group. 2010. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 14:R222. http://dx.doi.org/10.1186 /cc9365.
29. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 13: 180-195. http://dx.doi.org/10.1016/j.drup.2010.09.002.
30. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. 2014. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol 52:994-997. http://dx.doi.org/10.1128/JCM.03044-13.
31. Lion T. 2014. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev 27:441-462. http://dx.doi.org /10.1128/CMR.00116-13.
32. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813-1821. http://dx.doi.org/10.1086/588660.
33. Desnos-Ollivier M, Dromer F, Dannaoui E. 2008. Detection of caspofungin resistance in Candida spp. by Etest. J Clin Microbiol 46:2389-2392. http://dx.doi.org/10.1128/JCM.00053-08.
34. Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73-85. http://dx.doi.org/10.1016/S1473-3099(02)00181-0.
35. Florent M, Noel T, Ruprich-Robert G, Da Silva B, Fitton-Ouhabi V, Chastin C, Papon N, Chapeland-Leclerc F. 2009. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrob Agents Chemother 53:2982-2990. http: //dx.doi.org/10.1128/AAC.00880-08.
36. Papon N, Noel T, Florent M, Gibot-Leclerc S, Jean D, Chastin C, Villard J, Chapeland-Leclerc F. 2007. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrob Agents Chemother 51:369-371. http://dx.doi.org/10.1128/AAC.00824-06.
37. Chapeland-Leclerc F, Hennequin C, Papon N, Noel T, Girard A, Socie G, Ribaud P, Lacroix C. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54:1360-1362. http://dx.doi.org/10.1128/AAC.01138-09.
38. Grossman NT, Chiller TM, Lockhart SR. 2014. Epidemiology of echinocandin resistance in Candida. Curr Fungal Infect Rep 8:243-248. http: //dx.doi.org/10.1007/s12281-014-0209-7.
39. Pham CD, Iqbal N, Bolden CB, Kuykendall RJ, Harrison LH, Farley MM, Schaffner W, Beldavs ZG, Chiller TM, Park BJ, Cleveland AA, Lockhart SR. 2014. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690-4696. http://dx.doi.org/10.1128/AAC.03255-14.
40. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. 2014. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 20:1833-1840.
41. Cho EJ, Shin JH, Kim SH, Kim HK, Park JS, Sung H, Kim MN, Im HJ. 2015. Emergence of multiple resistance profiles involving azoles, echinocandins and amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia. J Antimicrob Chemother 70: 1268-1270. http://dx.doi.org/10.1093/jac/dku518.
42. Laverdière M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57:705-708. http://dx.doi.org/10.1093/jac/dkl022.
43. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
44. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5:e219. http://dx.doi.org/10.1371/journal.pmed.0050219.
45. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14:164-176. http: //dx.doi.org/10.1016/j.drup.2011.01.004.
46. Dunkel N, Blass J, Rogers PD, Morschhauser J. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol 69:827-840. http://dx.doi.org/10.1111/j.1365-2958.2008.06309.x.
47. Miller NS, Dick JD, Merz WG. 2006. Phenotypic switching in Candida lusitaniae on copper sulfate indicator agar: association with amphotericin B resistance and filamentation. J Clin Microbiol 44:1536-1539. http://dx.doi.org/10.1128/JCM.44.4.1536-1539.2006.
48. Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501-517.